Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke
Abstract
:1. Introduction
2. Results
2.1. Pathological TDP-43 Aggregates Specifically Expressed in the Damaged Infarcted Right Ischemic Cortex Regions in a Time-Dependent Manner
2.2. Augmented SOD2 and Reactive Astrogliosis after Acute Ischemic Stroke
2.3. Rapamycin Rescued Cell Viability and Decreased ROS Production after OGD Hypoxia
2.4. Rapamycin Decreased Infarction Volume and Improved Body Asymmetry
2.5. The Molecular Mechanism of Rapamycin in Attenuating Pathological TDP-43-Induced Neuronal Defects after Ischemic Stroke
3. Discussion
4. Materials and Methods
4.1. In Vitro Cell Culture Assay
4.2. Cell Viabilty Assay and ROS Production
4.3. In Vivo Animal Models
4.4. Middle Cerebral Artery (MCA) Ligation
4.5. Treatment
4.6. Histological Evaluation of Stroke Damage
4.7. Body Asymmetry
4.8. Sequential Biochemical Fractionation and Western Blotting
4.9. TUNEL Staining
4.10. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
Consent for Publication
References
- Virani, S.S.; Alvaro, A.; Benjamin, E.; Bittencourt, M.; Callaway, C.; Carson, A.; Chamberlain, A.; Chang, A.; Cheng, S.; Delling, F.; et al. Heart disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 2020, 141, e139–e596. [Google Scholar] [CrossRef] [PubMed]
- Al-Mufti, F.; Amuluru, K.; Roth, W.; Nuoman, R.; El-Ghanem, M.; Meyers, P.M. Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions. Neurosurgery 2018, 82, 781–789. [Google Scholar] [CrossRef]
- Pac-Soo, C.K.; Mathew, H.; Ma, D. Ischaemic conditioning strategies reduce ischaemia/reperfusion-induced organ injury. Br. J. Anaesth. 2015, 114, 204–216. [Google Scholar] [CrossRef] [Green Version]
- Nour, M.; Scalzo, F.; Liebeskind, D.S. Ischemia-reperfusion injury in stroke. Interv. Neurol 2013, 1, 185–199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- White, B.C.; Sullivan, J.M.; DeGracia, D.J.; O’Neil, B.J.; Neumar, R.W.; Grossman, L.I.; Rafols, J.A.; Krause, G.S. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. J. Neurol. Sci. 2000, 179, 1–33. [Google Scholar] [CrossRef]
- Sugawara, T.; Chan, P.H. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid. Redox Signal. 2003, 5, 597–607. [Google Scholar] [CrossRef] [PubMed]
- Granger, D.N.; Kvietys, P.R. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015, 6, 524–551. [Google Scholar] [CrossRef] [Green Version]
- Janardhan, V.; Qureshi, A.I. Mechanisms of ischemic brain injury. Curr. Cardiol. Rep. 2004, 6, 117–123. [Google Scholar] [CrossRef]
- Arai, T.; Hasegawa, M.; Akiyama, H.; Ikeda, K.; Nonaka, T.; Mori, H.; Mann, D.; Tsuchiya, K.; Yoshida, M.; Hashizume, Y.; et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351, 602–611. [Google Scholar] [CrossRef]
- Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C.M.; et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314, 130–133. [Google Scholar] [CrossRef]
- Ayala, Y.M.; Pantano, S.; D'Ambrogio, A.; Buratti, E.; Brindisi, A.; Marchetti, C.; Romano, M.; Baralle, F.E. Human, Drosophila, and C. elegans TDP43: Nucleic acid binding properties and splicing regulatory function. J. Mol. Biol. 2005, 348, 575–588. [Google Scholar] [CrossRef] [PubMed]
- Buratti, E.; Baralle, F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 2001, 276, 36337–36343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tamaki, Y.; Urushitani, M. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD. Int. J. Mol. Sci. 2022, 23, 12508. [Google Scholar] [CrossRef] [PubMed]
- Wu, M.; Zhang, H.; Kai, J.; Zhu, F.; Dong, J.; Xu, Z.; Wong, M.; Zeng, L.H. Rapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats. Ann. Clin. Transl. Neurol. 2018, 5, 138–146. [Google Scholar] [CrossRef] [PubMed]
- Gibbons, J.J.; Abraham, R.T.; Yu, K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 2009, 36 (Suppl. 3), S3–S17. [Google Scholar] [CrossRef]
- Ballou, L.M.; Lin, R.Z. Rapamycin and mTOR kinase inhibitors. J. Chem. Biol. 2008, 1, 27–36. [Google Scholar] [CrossRef] [Green Version]
- Bove, J.; Martinez-Vicente, M.; Vila, M. Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat. Rev. Neurosci. 2011, 12, 437–452. [Google Scholar] [CrossRef]
- Wang, I.F.; Guo, B.S.; Liu, Y.C.; Wu, C.C.; Yang, C.H.; Tsai, K.J.; Shen, C.K. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl. Acad. Sci. USA 2012, 109, 15024–15029. [Google Scholar] [CrossRef] [Green Version]
- Goossens, J.; Vanmechelen, E.; Trojanowski, J.Q.; Lee, V.M.; Van Broeckhoven, C.; van der Zee, J.; Engelborghs, S. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: A systematic review of existing antibodies. Acta Neuropathol. Commun. 2015, 3, 15. [Google Scholar] [CrossRef] [Green Version]
- Hasegawa, M.; Arai, T.; Nonaka, T.; Kametani, F.; Yoshida, M.; Hashizume, Y.; Beach, T.G.; Buratti, E.; Baralle, F.; Morita, M.; et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008, 64, 60–70. [Google Scholar] [CrossRef]
- Ren, Y.; Li, S.; Chen, S.; Sun, X.; Yang, F.; Wang, H.; Li, M.; Cui, F.; Huang, X. TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. Front. Neurol. 2021, 12, 663637. [Google Scholar] [CrossRef] [PubMed]
- Flynn, J.M.; Melov, S. SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic. Biol. Med. 2013, 62, 4–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ozaki, Y.; Nakata, Y.; Kameoka, M.; Hayashi, N.; Nakayama, Y.; Yagi, K. Clinical analysis of 104 cases of overdose in suicide attempts. Chudoku Kenkyu 2007, 20, 367–374. [Google Scholar] [PubMed]
- Kang, I.; Chu, C.T.; Kaufman, B.A. The mitochondrial transcription factor TFAM in neurodegeneration: Emerging evidence and mechanisms. FEBS Lett. 2018, 592, 793–811. [Google Scholar] [CrossRef] [Green Version]
- Morimoto, N.; Miyazaki, K.; Kurata, T.; Ikeda, Y.; Matsuura, T.; Kang, D.; Ide, T.; Abe, K. Effect of mitochondrial transcription factor a overexpression on motor neurons in amyotrophic lateral sclerosis model mice. J. Neurosci. Res. 2012, 90, 1200–1208. [Google Scholar] [CrossRef]
- Spronk, E.; Sykes, G.; Falcione, S.; Munsterman, D.; Joy, T.; Kamtchum-Tatuene, J.; Jickling, G.C. Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. Front. Neurol. 2021, 12, 661955. [Google Scholar] [CrossRef]
- Amado, B.; Melo, L.; Pinto, R.; Lobo, A.; Barros, P.; Gomes, J.R. Ischemic Stroke, Lessons from the Past towards Effective Preclinical Models. Biomedicines 2022, 10, 2561. [Google Scholar] [CrossRef]
- Del Zoppo, G.J.; Saver, J.L.; Jauch, E.C.; Adams, H.P., Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40, 2945–2948. [Google Scholar] [CrossRef] [Green Version]
- Lyerly, M.J.; Albright, K.C.; Boehme, A.K.; Shahripour, R.B.; Houston, J.T.; Rawal, P.V.; Kapoor, N.; Alvi, M.; Sisson, A.; Alexandrov, A.W.; et al. The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat? J. Neurol. Disord. Stroke 2013, 1, 1015. [Google Scholar]
- Berkhemer, O.A.; Fransen, P.S.; Beumer, D.; van den Berg, L.A.; Lingsma, H.F.; Yoo, A.J.; Schonewille, W.J.; Vos, J.A.; Nederkoorn, P.J.; Wermer, M.J.; et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015, 372, 11–20. [Google Scholar] [CrossRef] [Green Version]
- Bracard, S.; Ducrocq, X.; Mas, J.L.; Soudant, M.; Oppenheim, C.; Moulin, T.; Guillemin, F. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): A randomised controlled trial. Lancet Neurol. 2016, 15, 1138–1147. [Google Scholar] [CrossRef] [PubMed]
- Campbell, B.C.; Mitchell, P.J.; Kleinig, T.J.; Dewey, H.M.; Churilov, L.; Yassi, N.; Yan, B.; Dowling, R.J.; Parsons, M.W.; Oxley, T.J.; et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 2015, 372, 1009–1018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mocco, J.; Zaidat, O.O.; von Kummer, R.; Yoo, A.J.; Gupta, R.; Lopes, D.; Frei, D.; Shownkeen, H.; Budzik, R.; Ajani, Z.A.; et al. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. Stroke 2016, 47, 2331–2338. [Google Scholar] [CrossRef] [PubMed]
- Saver, J.L.; Goyal, M.; Bonafe, A.; Diener, H.C.; Levy, E.I.; Pereira, V.M.; Albers, G.W.; Cognard, C.; Cohen, D.J.; Hacke, W.; et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. 2015, 372, 2285–2295. [Google Scholar] [CrossRef] [Green Version]
- Jovin, T.G.; Chamorro, A.; Cobo, E.; de Miquel, M.A.; Molina, C.A.; Rovira, A.; San Román, L.; Serena, J.; Abilleira, S.; Ribó, M.; et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N. Engl. J. Med. 2015, 372, 2296–2306. [Google Scholar] [CrossRef] [Green Version]
- Goyal, M.; Demchuk, A.M.; Menon, B.K.; Eesa, M.; Rempel, J.L.; Thornton, J.; Roy, D.; Jovin, T.G.; Willinsky, R.A.; Sapkota, B.L.; et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015, 372, 1019–1030. [Google Scholar] [CrossRef] [Green Version]
- Radad, K.; Moldzio, R.; Al-Shraim, M.; Kranner, B.; Krewenka, C.; Rausch, W.D. Recent advances in autophagy-based neuroprotection. Expert Rev. Neurother. 2015, 15, 195–205. [Google Scholar] [CrossRef]
- Meng, Y.; Yong, Y.; Yang, G.; Ding, H.; Fan, Z.; Tang, Y.; Luo, J.; Ke, Z.J. Autophagy alleviates neurodegeneration caused by mild impairment of oxidative metabolism. J. Neurochem. 2013, 126, 805–818. [Google Scholar] [CrossRef] [Green Version]
- Ray, S.K. Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury. Neural Regen. Res. 2020, 15, 1601–1612. [Google Scholar] [CrossRef]
- Doeppner, T.R.; Coman, C.; Burdusel, D.; Ancuta, D.L.; Brockmeier, U.; Pirici, D.N.; Yaoyun, K.; Hermann, D.M.; Popa-Wagner, A. Long-term treatment with chloroquine increases lifespan in middle-aged male mice possibly via autophagy modulation, proteasome inhibition and glycogen metabolism. Aging 2022, 14, 4195–4210. [Google Scholar] [CrossRef]
- Filfan, M.; Olaru, A.; Udristoiu, I.; Margaritescu, C.; Petcu, E.; Hermann, D.M.; Popa-Wagner, A. Long-term treatment with spermidine increases health span of middle-aged Sprague-Dawley male rats. Geroscience 2020, 42, 937–949. [Google Scholar] [CrossRef] [PubMed]
- Krakauer, T.; Buckley, M. Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock. Toxins 2012, 4, 718–728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tran, C.M.; Mukherjee, S.; Ye, L.; Frederick, D.W.; Kissig, M.; Davis, J.G.; Lamming, D.W.; Seale, P.; Baur, J.A. Rapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue. Diabetes 2016, 65, 927–941. [Google Scholar] [CrossRef] [Green Version]
- Omileke, D.; Pepperall, D.; Bothwell, S.W.; Mackovski, N.; Azarpeykan, S.; Beard, D.J.; Coupland, K.; Patabendige, A.; Spratt, N.J. Ultra-Short Duration Hypothermia Prevents Intracranial Pressure Elevation Following Ischaemic Stroke in Rats. Front. Neurol. 2021, 12, 684353. [Google Scholar] [CrossRef] [PubMed]
- Janssens, J.; Van Broeckhoven, C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum. Mol. Genet. 2013, 22, R77–R87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lagier-Tourenne, C.; Cleveland, D.W. Rethinking ALS: The FUS about TDP-43. Cell 2009, 136, 1001–1004. [Google Scholar] [CrossRef] [Green Version]
- Ling, S.C.; Albuquerque, C.P.; Han, J.S.; Lagier-Tourenne, C.; Tokunaga, S.; Zhou, H.; Cleveland, D.W. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA 2010, 107, 13318–13323. [Google Scholar] [CrossRef] [Green Version]
- Pesiridis, G.S.; Lee, V.M.; Trojanowski, J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009, 18, R156–R162. [Google Scholar] [CrossRef] [Green Version]
- Watanabe, S.; Kaneko, K.; Yamanaka, K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J. Biol. Chem. 2013, 288, 3641–3654. [Google Scholar] [CrossRef] [Green Version]
- Barmada, S.J.; Skibinski, G.; Korb, E.; Rao, E.J.; Wu, J.Y.; Finkbeiner, S. Cytoplasmic Mislocalization of TDP-43 Is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis. J. Neurosci. 2010, 30, 639–649. [Google Scholar] [CrossRef] [Green Version]
- Wang, P.; Deng, J.; Dong, J.; Liu, J.; Bigio, E.H.; Mesulam, M.; Wang, T.; Sun, L.; Wang, L.; Lee, A.Y.; et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019, 15, e1007947. [Google Scholar] [CrossRef] [PubMed]
- Kanazawa, M.; Kakita, A.; Igarashi, H.; Takahashi, T.; Kawamura, K.; Takahashi, H.; Nakada, T.; Nishizawa, M.; Shimohata, T. Biochemical and histopathological alterations in TAR DNA-binding protein-43 after acute ischemic stroke in rats. J. Neurochem. 2011, 116, 957–965. [Google Scholar] [CrossRef] [PubMed]
- Lee, E.B.; Lee, V.M.; Trojanowski, J.Q.; Neumann, M. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 2008, 115, 305–311. [Google Scholar] [CrossRef] [PubMed]
- Caccamo, A.; Majumder, S.; Deng, J.J.; Bai, Y.; Thornton, F.B.; Oddo, S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J. Biol. Chem. 2009, 284, 27416–27424. [Google Scholar] [CrossRef] [Green Version]
- Scotter, E.L.; Vance, C.; Nishimura, A.L.; Lee, Y.B.; Chen, H.J.; Urwin, H.; Sardone, V.; Mitchell, J.C.; Rogelj, B.; Rubinsztein, D.C.; et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J. Cell Sci. 2014, 127, 1263–1278. [Google Scholar] [CrossRef] [Green Version]
- Hansel, G.; Ramos, D.B.; Delgado, C.A.; Souza, D.G.; Almeida, R.F.; Portela, L.V.; Quincozes-Santos, A.; Souza, D.O. The potential therapeutic effect of guanosine after cortical focal ischemia in rats. PLoS ONE 2014, 9, e90693. [Google Scholar] [CrossRef] [Green Version]
- Chang, C.F.; Lin, S.Z.; Chiang, Y.H.; Morales, M.; Chou, J.; Lein, P.; Chen, H.L.; Hoffer, B.J.; Wang, Y. Intravenous administration of bone morphogenetic protein-7 after ischemia improves motor function in stroke rats. Stroke 2003, 34, 558–564. [Google Scholar] [CrossRef] [Green Version]
- Tomac, A.C.; Agulnick, A.D.; Haughey, N.; Chang, C.F.; Zhang, Y.; Backman, C.; Morales, M.; Mattson, M.P.; Wang, Y.; Westphal, H.; et al. Effects of cerebral ischemia in mice deficient in Persephin. Proc. Natl. Acad. Sci. USA 2002, 99, 9521–9526. [Google Scholar] [CrossRef] [Green Version]
- Chang, C.F.; Morales, M.; Chou, J.; Chen, H.L.; Hoffer, B.; Wang, Y. Bone morphogenetic proteins are involved in fetal kidney tissue transplantation-induced neuroprotection in stroke rats. Neuropharmacology 2002, 43, 418–426. [Google Scholar] [CrossRef]
- Chang, C.F.; Niu, K.C.; Hoffer, B.J.; Wang, Y.; Borlongan, C.V. Hyperbaric oxygen therapy for treatment of postischemic stroke in adult rats. Exp. Neurol. 2000, 166, 298–306. [Google Scholar] [CrossRef]
- Al Shoyaib, A.; Archie, S.R.; Karamyan, V.T. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? Pharm. Res. 2019, 37, 12. [Google Scholar] [CrossRef] [PubMed]
- Ohshima, M.; Taguchi, A.; Tsuda, H.; Sato, Y.; Yamahara, K.; Harada-Shiba, M.; Miyazato, M.; Ikeda, T.; Iida, H.; Tsuji, M. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev. 2015, 37, 376–386. [Google Scholar] [CrossRef] [PubMed]
- Woodrum, C.; Nobil, A.; Dabora, S.L. Comparison of three rapamycin dosing schedules in A/J Tsc2+/− mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J. Transl. Med. 2010, 8, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Isayama, K.; Pitts, L.H.; Nishimura, M.C. Evaluation of 2,3,5-triphenyltetrazolium chloride staining to delineate rat brain infarcts. Stroke 1991, 22, 1394–1398. [Google Scholar] [CrossRef] [Green Version]
- Borlongan, C.V.; Cahill, D.W.; Sanberg, P.R. Locomotor and passive avoidance deficits following occlusion of the middle cerebral artery. Physiol. Behav. 1995, 58, 909–917. [Google Scholar] [CrossRef]
- Borlongan, C.V.; Hida, H.; Nishino, H. Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery. Neuroreport 1998, 9, 3615–3621. [Google Scholar] [CrossRef]
- Luo, Y.; Kuo, C.C.; Shen, H.; Chou, J.; Greig, N.H.; Hoffer, B.J.; Wang, Y. Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann. Neurol. 2009, 65, 520–530. [Google Scholar] [CrossRef] [Green Version]
- Winton, M.J.; Igaz, L.M.; Wong, M.M.; Kwong, L.K.; Trojanowski, J.Q.; Lee, V.M. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008, 283, 13302–13309. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tsou, Y.-S.; Lai, J.-H.; Chen, K.-Y.; Chang, C.-F.; Huang, C.-C. Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke. Int. J. Mol. Sci. 2023, 24, 676. https://doi.org/10.3390/ijms24010676
Tsou Y-S, Lai J-H, Chen K-Y, Chang C-F, Huang C-C. Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke. International Journal of Molecular Sciences. 2023; 24(1):676. https://doi.org/10.3390/ijms24010676
Chicago/Turabian StyleTsou, Yi-Syue, Jing-Huei Lai, Kai-Yun Chen, Cheng-Fu Chang, and Chi-Chen Huang. 2023. "Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke" International Journal of Molecular Sciences 24, no. 1: 676. https://doi.org/10.3390/ijms24010676